Pharmacotherapy for chronic obstructive pulmonary disease
In-Ae KIM; Yong-Bum PARK; Kwang-Ha YOO.
Journal of the Korean Medical Association
; : 545-551, 2018.
ArtÃculo en Ko | WPRIM | ID: wpr-766537
Documentos relacionados
The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation.
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer.
Natural Phosphodiesterase-4 Inhibitors with Potential <i>Anti</i>-Inflammatory Activities from <i>Millettia dielsiana</i>.
Acute PDE4 Inhibition Induces a Transient Increase in Blood Glucose in Mice.
Preferential PDE4B Inhibition - A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis.
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis.
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis.